Right ventricular dysfunction secondary to pulmonary disease — most often chronic hypoxic pulmonary disease.
Also known as: cor pulmonale, right heart failure, pulmonary heart disease
Overview
Right ventricular structural and functional changes (hypertrophy, dilation, and ultimately failure) caused by disease of the lung parenchyma, pulmonary vasculature, ventilation, or chest wall. By convention, RV dysfunction due to left heart disease, primary cardiomyopathy, or congenital heart disease is NOT considered cor pulmonale.
Epidemiology
Most commonly results from chronic obstructive pulmonary disease (COPD), accounting for ~80% of cases. Other causes include interstitial lung disease, obesity hypoventilation syndrome, chronic thromboembolic pulmonary hypertension (CTEPH), high-altitude exposure, and chest wall disorders. Prevalence rises with COPD severity.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Cor Pulmonale outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Pulmonary arterial hypertension (when it leads to RV failure, terminology varies but functional impact is similar)
Pathophysiology
Chronic alveolar hypoxia → hypoxic pulmonary vasoconstriction (an adaptive response intended to match perfusion to ventilation in local areas but maladaptive when global). Persistent vasoconstriction plus structural vascular remodeling and rarefaction of the pulmonary capillary bed elevate pulmonary vascular resistance. The RV initially hypertrophies in response to increased afterload but progressively dilates and fails as PA pressures and resistance climb. Hypercapnia and acidemia further amplify pulmonary vasoconstriction. Polycythemia from chronic hypoxia increases blood viscosity and worsens the burden on the RV.
Clinical presentation
Symptoms
Exertional dyspnea and fatigue (the underlying lung disease usually predominates early)
Exertional or syncopal episodes (advanced)
Lower extremity edema, abdominal bloating, early satiety, anorexia
Right upper quadrant discomfort from hepatic congestion
Signs / physical exam
Elevated JVP with prominent V wave (TR), Kussmaul sign in some cases
Right ventricular heave (parasternal lift)
Loud P2, fixed or paradoxical split S2 in some cases
Right-sided S3 or S4 gallop
Holosystolic murmur of tricuspid regurgitation at the LLSB, increased with inspiration (Carvallo sign)
Clubbing, cyanosis, and other features of the underlying lung disease (e.g., barrel chest in COPD)
Classic findings
Severe COPD patient with elevated JVP, lower extremity edema, and loud P2 — RV failure superimposed on chronic lung disease.
Differential diagnosis
Left-sided heart failure with secondary pulmonary venous hypertension — Elevated LV filling pressures on echo, history of HTN/CAD; PCWP >15 mmHg on RHC distinguishes
Pulmonary arterial hypertension (PAH, WHO Group 1) — Often younger patient, idiopathic or connective tissue disease association; precapillary by RHC; treated with PAH-specific therapies
Constrictive pericarditis — Equalization of diastolic pressures, pericardial thickening on CT/MRI; can mimic right HF
Thyroid studies, HIV, autoimmune serologies if PAH etiology uncertain
Imaging
Transthoracic echocardiography — estimates RV size, function, and pulmonary artery systolic pressure via tricuspid regurgitation jet; assesses for left heart disease
ECG: right axis deviation, right ventricular hypertrophy, P-pulmonale (peaked P waves >2.5 mm in II, III, aVF), RBBB, right atrial enlargement
CXR: enlarged pulmonary arteries (right descending PA >16 mm), prominent RV, oligemic peripheral lung fields ('pruning'); features of underlying lung disease (hyperinflation, fibrosis)
High-resolution CT chest if interstitial lung disease suspected
V/Q scan to screen for chronic thromboembolic pulmonary hypertension (CTEPH) — preferred over CTPA
Polysomnography if OSA suspected
Right heart catheterization — gold standard; defines pulmonary hemodynamics (mean PAP, PCWP, PVR, cardiac output) and distinguishes pre- from post-capillary pulmonary hypertension
Diagnostic algorithm
Feature
Cor Pulmonale
Left-Sided HF
Underlying disease
Lung parenchyma, vasculature, or thoracic cage
CAD, HTN, valvular, cardiomyopathy
JVP
Elevated, prominent V wave
Elevated
Lung exam
Wheezing, decreased breath sounds, or fibrotic crackles
Bibasilar fine crackles, pleural effusion
Echo
Dilated RV, normal LV, elevated PASP, normal PCWP
Dilated/dysfunctional LV, elevated PCWP
Pulmonary HTN type
Group 3 (lung disease) or 4 (CTEPH)
Group 2 (left heart disease)
Mortality-reducing therapy
Long-term oxygen (when criteria met)
GDMT (ACEi/ARNI, beta-blocker, MRA, SGLT2i)
Distinguishing cor pulmonale from left-sided heart failure.
Treatment
First-line
Treat the underlying lung disease aggressively — this is the cornerstone of management
Long-term oxygen therapy (LTOT) is the single intervention shown to reduce mortality in COPD-related cor pulmonale; indicated for resting PaO2 ≤55 mmHg or SpO2 ≤88%, or PaO2 56-59 / SpO2 ≤89% with cor pulmonale, polycythemia, or peripheral edema. Target SpO2 88-92% in COPD
Treat OSA with CPAP / BiPAP; obesity hypoventilation with NIV
Diuretics (furosemide, torsemide) for volume overload — use cautiously to avoid reducing preload too aggressively in a preload-dependent failing RV
Second-line / adjunct
Anticoagulation for CTEPH (chronic warfarin or DOACs); pulmonary endarterectomy is potentially curative in operable disease, with riociguat or balloon pulmonary angioplasty for inoperable CTEPH
PAH-specific therapy (endothelin receptor antagonists, PDE5 inhibitors, prostacyclins, guanylate cyclase stimulators) is NOT recommended for cor pulmonale from hypoxic lung disease and may worsen V/Q mismatch and oxygenation; reserved for confirmed WHO Group 1 PAH
Phlebotomy considered for hematocrit >55-65% with symptomatic hyperviscosity
Lung transplantation for end-stage disease unresponsive to medical management
Tricuspid regurgitation and dilation of the IVC and hepatic veins
Congestive hepatopathy and cardiac cirrhosis
Syncope, especially with exertion
Polycythemia with thromboembolic complications
PANCE pearls
Cor pulmonale is RV dysfunction due to LUNG disease — RV failure from left heart disease, congenital lesions, or primary RV cardiomyopathy is excluded by definition.
Long-term oxygen therapy is the only intervention proven to improve survival in COPD-related cor pulmonale.
PAH-specific therapies (endothelin antagonists, PDE5 inhibitors, prostacyclins) can worsen oxygenation in cor pulmonale from hypoxic lung disease by impairing hypoxic vasoconstriction and worsening V/Q mismatch.
P-pulmonale (peaked P waves >2.5 mm in II, III, aVF) signifies right atrial enlargement.
Always evaluate for chronic thromboembolic disease (CTEPH) in unexplained pulmonary hypertension — V/Q scan is the screening test of choice and CTEPH is potentially curable with pulmonary endarterectomy.
References
ESC/ERS 2022 — 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension (Humbert et al., Eur Heart J 2022)
GOLD 2024 — Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 Report
NOTT and MRC trials — Continuous or Nocturnal Oxygen Therapy in Hypoxemic Chronic Obstructive Lung Disease (NOTT, Ann Intern Med 1980); MRC Long-term Domiciliary Oxygen Trial (Lancet 1981)
Practice Cardiovascular questions on FirstPassPA
Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.